百济神州、宜联新药IND!礼来重金加注、AZ联合疗法新进展

医药经济报
07 May

百济神州1类新药获批临床日前,CDE官网公示,百济神州申报的1类新药BGB-45035片就新适应症获得临床试验默示许可,拟开发治疗结节性痒疹。BGB-45035片是一款靶向IRAK4的蛋白降解剂(IRAK4 CDAC),该产品于2024年8月首次在中国获批IND,用于治疗中重度特应性皮炎。截图来源:CDE官网据百济神州公开资料,BGB-45035具有多个优势,有希望开发成为“best-in-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10